- Home
- MNTSW vs MRK Comparison
MNTSW vs MRK Comparison
Compare MNTSW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNTSW | MRK |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 123 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 268.7B |
| IPO Year | 2019 | 1994 |
Fundamental Metrics
Financial Performance| Metric | MNTSW | MRK |
|---|---|---|
| Price | $0.01 | $114.44 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $124.29 |
| AVG Volume (30 Days) | 117.3K | ★ 7.4M |
| Earning Date | N/A | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.97% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | N/A | ★ 7.28 |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | N/A | $3.74 |
| Revenue Next Year | N/A | $5.47 |
| P/E Ratio | ★ N/A | $15.72 |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $0.01 | $75.40 |
| 52 Week High | $0.10 | $125.14 |
Technical Indicators
Market Signals| Indicator | MNTSW | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 47.88 | 42.04 |
| Support Level | $0.01 | $113.82 |
| Resistance Level | $0.03 | $125.14 |
| Average True Range (ATR) | 0.00 | 2.66 |
| MACD | 0.00 | -0.89 |
| Stochastic Oscillator | 18.50 | 9.81 |
Price Performance
Historical ComparisonAbout MNTSW Momentus Inc.
Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).